Study of Visfatin Level in Type 1 Diabetic Children and Adolescents

Mona H. El Samahi, Nagwa Abdallah Ismail, Randa M. Matter, Abeer Selim, Alshaymaa Ahmed Ibrahim, Walaa Nabih

Abstract


BACKGROUND: Visfatin is an intracellular enzyme, known as nicotinamide phosphoribosyltransferase (Nampt) and pre-B-cell colony-enhancing factor (PBEF-1). It has insulin-mimetic effects and lowers plasma glucose levels.

AIM: The aim of the work was to assess serum concentration of Visfatin in type 1 diabetic children and adolescents and study its relationships with duration of diabetes, body mass index (BMI), glycemic control, insulin dosage, lipid profile and microvascular complications.

MATERIAL AND METHODS: Fifty children and adolescents with type 1 diabetes mellitus were recruited with 30 ages and gender-matched healthy subjects. They were subjected to history taking; anthropometric measurements and chronic diabetic complications were recorded if present. Laboratory analysis included urinary microalbumin, serum triglycerides, HDL, LDL, cholesterol, fasting blood glucose, glycosylated Hb (HbA1c) and serum visfatin which was measured with enzyme-linked immunosorbent assay.

RESULTS: Diabetic patients showed highly significant decrease in the level of visfatin compared to the control group (P = 0.0001).There was significant further decrease in visfatin level in diabetics with microalbuminuria (n = 13) compared to normoalbuminuric patients (n = 37) (P = 0.015). There was highly significant inverse correlation between visfatin level with age (r = -0.379, p = 0.007), BMI (r = -0.418, p = 0.003), waist circumference (r = -0.430, p = 0.002), hip circumference (r = -0.389, p = 0.005) and microalbuminuria (r = -0.323, p = 0.022).

CONCLUSIONS: Type 1 diabetic children and adolescents had a significantly lower visfatin level compared to controls. A marked decrease in the level of visfatin was shown in patients with microalbuminuria with an inverse correlation with BMI suggesting an important role of visfatin in the pathogenesis of type 1 diabetics and type 1 diabetic nephropathy.

Keywords


Type 1 diabetes; Visfatin; complications; microalbuminuria

Full Text:

PDF OnlineFirst

References


American Diabetes Association (ADA). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2012 Jan; 35 (Supplement 1): S64-S71. https://doi.org/10.2337/dc12-S064.

Adeghate E. Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions. Current Medicinal Chemistry. 2008; 15:1851-1862. https://doi.org/10.2174/092986708785133004 PMid:18691043

Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307:426–430. https://doi.org/10.1126/science.1097243 PMid:15604363

Toruner F, Altinova N, Bukan N, Arslan E, Akbay E, Ersoy R, Arslan M Plasma visfatin concentrations in subjects with type 1 diabetes mellitus Horm Res. 2009; 72(1):33-7. https://doi.org/10.1159/000224338 PMid:19571557

Kang Y, Chang D, Song H, Lee M, Jee ko G. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes research and clinical practice. 2010; 89(2):141-149. https://doi.org/10.1016/j.diabres.2010.03.020 PMid:20409603

Haider D, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006; 43(4): 548-549. https://doi.org/10.1097/01.mpg.0000235749.50820.b3 PMid:17033537

Chen M, Chung F, Chang D, Tsai J, Huang H, Shin S. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91(1):295–9. https://doi.org/10.1210/jc.2005-1475 PMid:16234302

Olszanecka-Glinianowicz M, Kocełak P, Nylec M, et al. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci. 2012; 8(2): 214-218. https://doi.org/10.5114/aoms.2012.28547 PMid:22661992 PMCid:PMC3361032

López-Bermejo A, Chico-Julià, B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernández-Real J. Serum visfatin increases with progressive beta-cell deterioration. Diabetes. 2006; 55(10): 2871-5. https://doi.org/10.2337/db06-0259 PMid:17003355

Sempe M, Pedron G and Roy-Pernot NP. Auxologic methods et sequences Paris: Laboratoire Theraplix, 1979.

Hirschler V, Bugna J, Roque M, Gilligan T, Gonzalez C .Does Low Birth Weight Predict Obesity/ Overweight and Metabolic Syndrome in Elementary School Children?. Archives of Medical Research. 2008; 39(8): 796-802. https://doi.org/10.1016/j.arcmed.2008.08.003 PMid:18996294

Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982; 1 (8287): 1430-2. https://doi.org/10.1016/S0140-6736(82)92450-3

Sacks DB. Carbohydrates. In: Tietz textbook of clinical chemistry. 4th ed. C.A. Burits, E.R. Ashwood and D.E. Bruns (Eds). Philadelphia, W.B. Saunders Co., 2006: pp. 837-872.

Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM . Glycated hemoglobin: methodologies and clinical applications. Clin Chem. 1986; 32(10 Suppl):B64-B70. PMid:3530542

Alexiadou K, Kokkinos A, Liatis S, Perrea D, Katsilambros N, Tentolouris N. Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones. 2012; 11(4):444:450.

Dogru T, Sonmez A, Tasci I, Bozoglu A, Yilmaz M, Genc H, Erdema G, Gok M, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance Diabetes Res Clin Pract. 2007; 76(1):24-29. https://doi.org/10.1016/j.diabres.2006.07.031 PMid:16956691

Hassan A, Arshad N. Assessment of Visfatin and Risk Factors in Relation with Diabetic Mellitus Type II. Life Science Journal. 2014;11(9s) http:www.lifescience.com.

Wang P, Greevenbroek M, Bouwman F, Brouwers M, van der Kallen C, Smit E. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. European Journal of Physiology. 2007; 454 (6): 971-976. https://doi.org/10.1007/s00424-007-0262-y PMid:17429683

Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol Diabetes control and clinical practice. 2008; 79 (2): 412 – 418.

El-Mesallamy H, Kassem H, El-Demerdash E, Amin A . Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 2010; 60:63–70. https://doi.org/10.1016/j.metabol.2010.04.008 PMid:20605615

Song H, Lee M, Kim B, Park Y, Ko G, Kang Y, Han J, Han S, Han K, Kim H, Cha D. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol. 2008; 295: 1485–1494. https://doi.org/10.1152/ajprenal.90231.2008 PMid:18768589

Huang Q, Guo Y, Zeng H, Xie W, Yan H, Ding H . Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res. 2011; 36: 93–100. https://doi.org/10.3109/07435800.2010.539992 PMid:21314328

Yilmaz M, Saglam M, Carrero J, Qureshi A, Caglar K, Eyileten T, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/nampt. A novel marker of endothelial damage? Clin Transplant. 2009; 23:241– 248. https://doi.org/10.1111/j.1399-0012.2008.00921.x PMid:19402217

Mahmood N, Junejo AM, Jamal Q, Awan R. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. J Pak Med Assoc. 2010; 60(11):922-6. PMid:21375196

Samara A, Pfister M, Marie B, Visvikis-seist S. Visfatin, low- grade inflammation and body mass index (BMI). Clin Endocrinol (Oxf). 2008; 69(4):568-574. https://doi.org/10.1111/j.1365-2265.2008.03205.x PMid:18248642

Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci. 2015;11:463–82. https://doi.org/10.5114/aoms.2015.52350 PMid:26170839 PMCid:PMC4495144

RedondoMJ, Rodriguez LM, Haymond MW, Hampe CS, Smith EO, Balasubramanyam A. Serum adiposity-induced biomarkers in obese and lean child. Pediatr Diabetes. 2014;15(8):543-9. https://doi.org/10.1111/pedi.12159 PMid:24978596 PMCid:PMC4423898

Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf). 2007; 67:796–800. https://doi.org/10.1111/j.1365-2265.2007.02966.x PMid:17634078

Dogru T, Sonmez A, Tasci I, Bozoglu A, Yilmaz M, Genc H, Erdema G, Gok M, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance Diabetes Res Clin Pract. 2007; 76(1):24-29. https://doi.org/10.1016/j.diabres.2006.07.031 PMid:16956691

Berndt J, Klöting N, Kralisch S, Kovacs P,Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005; 54(10):2911-291. https://doi.org/10.2337/diabetes.54.10.2911 PMid:16186392




DOI: http://dx.doi.org/10.3889/oamjms.2017.065

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Mona H. El Samahi, Nagwa Abdallah Ismail, Randa M. Matter, Abeer Selim, Alshaymaa Ahmed Ibrahim, Walaa Nabih

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 



Published by: Id Design 2012/DOOEL Skopje, Republic of Macedonia